Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity
Programmatic research outcomes used to establish the evidencebase of dementia caregiving support programs: An analysis of Best Programs for Caregiving
Most of us yearn for bright and glowing skin and have already tried the numerous skin care products available on the market, but in vain
The 2022 publication of revised consensus diagnostic criteria for multiple system atrophy and the emergence of promising biomarkers provides a thorough diagnostic framework that now enables the diagnosis of numerous acquired causes of SLOCA, including autoimmune disorders and neurodegenerative diseases
The unique blend of ingredients makes this product perfect for pets with EPI
Long-Acting Amylin Agonist GUB014295 Gubra A/S (Hrsholm, Denmark), a biotech company specialized in pre-clinical contract research, initiated a phase 1 clinical trial (NCT06144684) to investigate the safety, tolerability and pharmacological properties of GUB014295 (GUBamy), a long-acting OW SC amylin agonist, in healthy volunteers [117]